European Biotech Acquisition Corp.
EBAC
NASDAQ Capital Market11.19
USD
-0.52
- -
CIK
0001841258
ISIN
KYG3167F1028
CUSIP
G3167F102
Return %
Stock
S&P500
1Y
14.89
18.21
3Y
15.36
64.38
5Y
15.36
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eduardo Bravo Fernandez de Araoz
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- Johannes Vermeerplein 9 Amsterdam Netherlands 1071 DV
- IPO Date
- May 11, 2021
- CIK
- 0001841258
- Website
- lspvc.com
- Similar Companies
- Business
- European Biotech Acquisition Corp. (EBAC) operates as a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting high-potential companies in the European life sciences industry; its focus includes therapeutics with breakthrough potential, strong management teams, near-term value inflection points, and suitability for strategic exits through M&A. Incorporated on January 8, 2021, as a Cayman Islands exempted company and headquartered in Amsterdam, Netherlands, EBAC lacks significant independent operations and relies on its sponsor affiliate, LSP (now part of EQT Life Sciences), a leading European healthcare investor with over 30 years of experience, offices in Amsterdam, Munich, and Boston, and more than $2.3 billion raised across funds investing in private and public equity markets in Europe and the United States. The company conducted a $127 million Nasdaq IPO in March 2021 under ticker EBAC and maintains trading activity as of late 2025 with a market capitalization around $148 million, institutional ownership, and short interest. In its most significant development, EBAC completed a reverse merger with Switzerland-based biopharmaceutical company Oculis SA on March 2, 2023, pursuant to a definitive business combination agreement announced October 17, 2022, valued at approximately $220 million enterprise value; the transaction provided gross proceeds exceeding $200 million from EBAC's trust, PIPE investments anchored by LSP 7 and participants including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, Tekla Capital Management, and VI Partners, with Oculis shares subsequently listing on Nasdaq under ticker OCS while EBAC's units, common stock, and warrants were suspended from trading. No further mergers, acquisitions, funding rounds, product launches, or major strategic shifts have been reported for EBAC in 2024 or 2025, positioning it as a dormant SPAC post-combination with ongoing market presence.
European Biotech Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report